TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01110629
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily dose: 3 tablets TID for 8 weeks.
Study: NCT00197379
Drug: roxithromycin
Normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03081416
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03081416
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard therapy
Study: NCT01416883
Drug: ICI176,334-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will receive single dose of ICI176,334-1
Study: NCT02151708
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
Study: NCT02151708
Drug: motilitone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
Study: NCT02479854
Drug: Asmakast
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 chewable tablet contains 5 mg montelukast
Study: NCT00548860
Drug: Standard Medical Care (SMC)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04262336
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable sterile viscous solution of sodium hyaluronate in sodium chloride
Study: NCT02796807
Drug: 68Ga-HBED-CC-PSMA (DKFZ-11) PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01125215
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical cream base of nanoparticle apply to area with neuropathic pain twice daily for 12 weeks
Study: NCT01310322
Drug: AZD5423
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for injection, administered as intravenous infusion Corr to total dose of 250µg AZD5423
Study: NCT01310322
Drug: AZD5423
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423
Study: NCT01310322
Drug: AZD5423
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423
Study: NCT01310322
Drug: AZD5423
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
Study: NCT00620594
Drug: BEZ235
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01263574
Drug: 70% ethanol
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL SPRAY [Anatizer S 70% Ethanol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of the lock solution will occur between cycles of parenteral nutrition. Lock solutions will be administered three days per week. The pre-measured volume of lock solution will then be injected into the catheter for 4 hours. Prior to the next instillation of medications into the catheter, the lock solution will be aspirated and discarded. Another 5mL flush of saline will then be instilled into the catheter prior to medication or parenteral nutrition administration. Volume of lock solution administered will be determined by catheter size.
Study: NCT00005861
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01332942
Drug: BAY85-3934
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received an oral single dose of placebo tablet matched to the molidustat dose (BAY85-3934) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).
Study: NCT01332942
Drug: BAY85-3934
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received an oral single dose of 5 mg of molidustat IR tablet on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
Study: NCT01332942
Drug: BAY85-3934
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received an oral single dose of 10 mg of molidustat ( 2x 5mg IR tablets) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).
Study: NCT01332942
Drug: BAY85-3934
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received an oral single dose of 25 mg of molidustat (1 x 20 mg IR tablet and 1 x 5 mg IR tablet) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
Study: NCT01332942
Drug: BAY85-3934
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received an oral single dose of 50 mg) of molidustat (2 x 20 mg IR tablets and 2 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
Study: NCT01332942
Drug: BAY85-3934
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received an oral single dose of 75 mg of molidustat (3 x 20 mg IR tablets and 3 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
Study: NCT03007394
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill to mimic lorcaserin 10mg capsule
Study: NCT04382911
Drug: 18F-fluoroestradiol
Normalized name: fluoroestradiol (18F)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive the FES tracer during a PET/MRI scan
Study: NCT01794104
Drug: LMP400
Normalized name: LMP400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Top1 inhibitors such as LMP400 are potent anticancer agents because stabilizing cleavage complex formation induces replication-and transcription-mediated DNA damage and delays DNA repair, leading to apoptosis. Preclinical and clinical data indicate that baseline tumor levels of Top1 correlate strongly with ability to respond to Top1 inhibitor therapy.
Study: NCT04201561
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (40 ml) will be administered before chemotherapy in patients assigned to the control group.
Study: NCT04201561
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175mg/m2), carboplatin (AUC 5.0 or 6.0) IV, and bevacizumab IV (15mg/kg) D1, every three weeks.
Study: NCT01469468
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 1: Single dose of simvastatin 20 mg Day 8: single dose of simvastatin 20 mg (with PF-05175157)
Study: NCT01120210
Drug: JNJ-39588146 5 ng/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour infusion of JNJ-39588146 5 ng/kg/min on Day 1
Study: NCT01120210
Drug: JNJ-39588146 15 ng/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour infusion of JNJ-39588146 15 ng/kg/min on Day 1
Study: NCT01120210
Drug: JNJ-39588146 30 ng/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour infusion of JNJ-39588146 30 ng/kg/min on Day 1
Study: NCT01120210
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour infusion of matching placebo on Day 1
Study: NCT01120210
Drug: JNJ-39588146 5, 15, or 30 ng/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18-hour infusion of JNJ-39588146 or matching placebo on Day 1 immediately folllowing the 3-hour infusion at a dose equal to the maximum dose tolerated by that patient during the 3-hour infusion in Part 1 of the study.
Study: NCT03618797
Drug: HL-PIF cap.160/2mg + Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate pellet (as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
Study: NCT03618797
Drug: Livalo tab. 2mg + Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin ca 2mg
Study: NCT04296396
Drug: Fixed opioid prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 tablets of oxycodone 5mg
Study: NCT02043015
Drug: Pre-exposure prophylaxis with FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: For men who meet eligibility criteria, PrEP with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit. Men who accept PrEP will be required to have clinic visits, in addition to the regularly scheduled study visits, one month after starting PrEP and at least every 3 months afterward to monitor blood creatinine, AST/ALT and phosphorus levels.
Study: NCT00974571
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet orally once daily at bedtime for 6 weeks
Study: NCT03423732
Drug: CardioCell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the N-O CLI trial will receive a full dose of IMP three times during the trial: at baseline, after 45 days post index administration and after 3 months post index administration.~IMP will be administered into femoral artery and intramuscularly with 50:50 proportion. The intramuscularly dose will be administered into muscles above and below the knee in 50:50 proportion.
Study: NCT03423732
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.~Control group will receive the same amount of fluid used for WJMSCs preparation, without cells.
Study: NCT02927457
Drug: GSK2646264 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: A cream for topical application with a concentration of 1% GSK2646264.
Study: NCT02927457
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive matching Placebo topically.
Study: NCT01857063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo chewable tablets, taken orally once daily at bedtime for 7 days
Study: NCT02149433
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01573624
Drug: FF/GSK573719
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100/15.6
Study: NCT01573624
Drug: FF/GSK573719
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100/31.25
Study: NCT01573624
Drug: FF/GSK573719
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100/62.5
Study: NCT01573624
Drug: FF/GSK573719
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100/125
Study: NCT01573624
Drug: FF/GSK573719
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100/250
Study: NCT00003585
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03306264
Drug: ASTX727
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASTX727 oral tablet
Study: NCT02202928
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.
Study: NCT04099667
Drug: Phase 2; Low Dose MYOBLOC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections on Day 1
Study: NCT04099667
Drug: Phase 2; High Dose MYOBLOC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections on Day 1
Study: NCT04099667
Drug: Phase 2; Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections on Day 1
Study: NCT04099667
Drug: Phase 3; MYOBLOC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections on Day 1
Study: NCT04099667
Drug: Phase 3; Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections on Day 1
Study: NCT04587622
Drug: Icenticaftor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 300 mg of icenticaftor (QBW251)
Study: NCT00153491
Drug: artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00675116
Drug: GW823296
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04021264
Drug: Dextrose 5
Normalized name: Dextrose 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection
Study: NCT01565291
Drug: florbetapir F 18
Normalized name: Florbetapir F 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection, 370MBq (10mCi), single dose
Study: NCT01289808
Drug: Glucose 25%
Normalized name: glucose 25% oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1ml of glucose 25% once
Study: NCT01289808
Drug: Glucose 25%
Normalized name: glucose 25% oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1ml glucose once per os
Study: NCT00960635
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: pill without agent
Study: NCT02294877
Drug: Vimizim® (elosulfase alfa)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant human N acetylgalactosamine 6 sulfatase (rhGALNS)
Study: NCT02850003
Drug: IDP-120 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel
Study: NCT00864474
Drug: CELSENTRI® Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: CELSENTRI ® Tablets 150mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage is 300 mg twice daily. Maraviroc must be used in combination with other anti-HIV drugs. The dosage may be adjusted according to co-administered medical products. Maraviroc can be taken with or without food.
Study: NCT00567775
Drug: inhaled human insulin
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01707004
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00727194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV weekly for 4 doses then every two weeks for 7 doses
Study: NCT01763164
Drug: MEK162
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEK162 will be administered as a fixed dose of 45 mg (3 x 15 mg tablets) BID, with a glass of water and taken with or without food.
Study: NCT01234129
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: zoledronic acid, 4 mg,standard dose,at monthly interval, by 2 years
Study: NCT03152318
Drug: rQNestin
Approvals — FDA: no, EMA: no, PMDA: no
Description: rQNestin is an oncolytic viral vector. It is administered via intratumoral injection during biopsy surgery.
Study: NCT03152318
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is an immunomodulating agent. It is administered intravenously in a single dose 2 days (+/- 6 hrs) before surgery.
Study: NCT02837432
Drug: Hydrocortisone acetate
Normalized name: Hydrocortisone Acetate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02837432
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05518279
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the control arm will receive 3 placebo pills while down in the Emergency Department after being diagnosed with a hip fracture. After they receive the placebo pills and are medically optimized for surgery, they will be taken to the operating room for fracture fixation.
Study: NCT00779454
Drug: Gemcitabine, Oxaliplatin, Capecitabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabin: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7
Study: NCT00779454
Drug: Panitumumab, Gemcitabine, Oxaliplatin, Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7 Panitumumab: 6 mg/kg day 1
Study: NCT00184899
Drug: Intravenous infusion of Intralipid/heparin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00184899
Drug: Intravenous infusion of Glycerol/heparin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00071812
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV plus standard therapy (SOC) for RA; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
Study: NCT01896895
Drug: IncobulinumtoxinA (Xeomin), 25 Units
Approvals — FDA: no, EMA: no, PMDA: no
Description: IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 25 Units per eye.
Study: NCT01896895
Drug: IncobotulinumtoxinA (Xeomin), 12.5 Units
Approvals — FDA: no, EMA: no, PMDA: no
Description: IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 12.5 Units per eye.
Study: NCT01896895
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Main Period: Placebo to IncobotulinumtoxinA (Xeomin), powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Study: NCT01896895
Drug: IncobotulinumtoxinA (Xeomin), 35 Units
Approvals — FDA: no, EMA: no, PMDA: no
Description: IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Open-Label Extension: up to 35 Units per eye.
Study: NCT01396369
Drug: Birth control plus Brevail
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests. After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day). The patients will return to the clinic for a follow up visit after 3 months. If no side effects, Brevail and OC will be continued for 3 more months. The control group will also have a follow up after 3 months of OC. Six months after the initiation of the study, the patients in the both groups will have another H\&P as well as repeat ultrasound and blood tests.
Study: NCT01484964
Drug: ASP015K
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03709927
Drug: ZTI-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6g IV fosfomycin
Study: NCT03692416
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infants and children with vasculitis attending AssiutU, aged \> 1 mo. - 17 yr. of both genders will be included during 2 years of study.~Besides full clinical history and thorough examination, all cases will have: CBC, CRP, ESR, Renal function tests \& Albumin / creatinine ratio.~All cases will have an initial estimation as well as follow up estimation after treatment by Ibuprofen for ANCA, C3, C4 \&C5a levels done, measured By ELISA technique.
Study: NCT00667342
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV.
Study: NCT00667342
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV.
Study: NCT01911507
Drug: INC280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03672435
Drug: Topical Solution
Normalized name: Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: proparacaine 0.5% eye drop
Study: NCT00394030
Drug: GSK716155 subcutaneous injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK716155 will be available as lyophilize uniform cake in 10 milliliter (mL) clear glass vials with 20 millimeter (mm) closure. Subjects will administer dose of either 16mg or 64mg of GSK716155 via subcutaneous injection(s). For dose of 16 mg 1 injection of 0.62 mL will be administered and for dose of 64 mg 3 injections of 0.82 mL each will be administered.
Study: NCT03734848
Drug: Bilateral Ultrasound Guided Pectoralis Nerve Block.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using a 20-gauge 5 cm needle. Injection bupivacaine 0.25% used as a local anesthetic. The block was performed in a supine position with the arm slightly abducted. The ultrasound probe was placed at the midclavicular level infero-laterally to locate the axillary artery and vein and then moved laterally toward the axilla until pectoralis major, pectoralis minor, and serratus anterior muscles were identified at the level of the fourth rib. The needle was inserted in-plane with respect to the ultrasound probe. A volume of 20 ml of local anesthetic solution was deposited in the fascial plane between pectoralis minor and serratus anterior muscle, followed by withdrawal of the needle to the fascial plane between the pectoralis major and pectoralis minor muscle, where a volume of 10 ml was deposited. The block was performed similarly on the opposite side. Care was taken not to cross the toxic dose of bupivacaine (3 mg/kg).
Study: NCT02178033
Drug: Split dose low-volume PEG solution
Normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®, Norgine, Harefield, United Kingdom); in the control arm the whole colonoscopy preparation is administered the day before colonoscopy; in the  active comparator  arm one liter of the bowel preparation is administered on the evening before the colonoscopy and the remaining liter on the day of the procedure.
Study: NCT01332617
Drug: Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Simvastatin 80 mg PO daily starting day -2 through day 10.~2. Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly~3. Bortezomib 1.3 mg/m2/day IV bolus on days 3,6 and 10.~4. Bendamustine 100 mg/m2/day IV over 30 minute infusion on days 3 and 10.~5. Methylprednisolone 1g/m2 IV over 30 minutes on days 1 and 8.
Study: NCT00460941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sc weekly
Study: NCT00003491
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.